OptimizeRx (OPRX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• OptimizeRx is expected to announce its Q2 2025 earnings, projecting a profit of $0.03 per share and revenue of $22.27 million, after the market closes on August 7th.
• Despite a previous earnings report showing a profit of $0.08 per share, the company has a negative net margin of 16.33% and is projected to post $0 EPS for both the current and next fiscal years.
• Brokerages have recently reaffirmed or upgraded their ratings on OptimizeRx, with a consensus rating of "Moderate Buy" and an average target price set at $10.81.

OptimizeRx (NASDAQ:OPRX - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $22.27 million for the quarter. OptimizeRx has set its FY 2025 guidance at EPS.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.19. OptimizeRx had a negative return on equity of 0.29% and a negative net margin of 16.33%. The firm had revenue of $21.93 million during the quarter, compared to analyst estimates of $18.69 million. On average, analysts expect OptimizeRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OptimizeRx Price Performance

OptimizeRx stock traded down $0.14 during mid-day trading on Monday, hitting $12.36. 230,582 shares of the company were exchanged, compared to its average volume of 367,141. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 0.25. The business has a fifty day moving average of $13.36 and a 200 day moving average of $9.60. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $15.71. The company has a market capitalization of $228.60 million, a PE ratio of -14.77, a price-to-earnings-growth ratio of 4.17 and a beta of 1.33.

Wall Street Analysts Forecast Growth

OPRX has been the subject of several recent analyst reports. JMP Securities increased their price objective on OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a research note on Tuesday, May 13th. Wall Street Zen upgraded OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Stifel Nicolaus increased their price objective on OptimizeRx from $12.50 to $16.00 and gave the stock a "buy" rating in a research note on Monday, June 9th. Roth Capital restated a "buy" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Finally, Citigroup restated an "outperform" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $10.81.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.